^
Association details:
| Biomarker: | SLC35A2 overexpression |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2
Published date:
05/18/2023
Excerpt:
Based on data from several clinical trials, patients with LUAD, LUSC, SKCM, and BLCA who exhibited high SLC35A2 expression may experience improved immunotherapy response. Therefore, SLC35A2 could be considered a potential predictive biomarker for the prognosis and immunotherapy efficacy of various tumors.
DOI:
10.3389/fimmu.2023.1155182
